Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYX NASDAQ:BDMD OTCMKTS:GTHP NASDAQ:NTRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$2.13$2.09$0.76▼$2.73$80.56M1.4356,687 shs19,303 shsBDMDBaird Medical Investment$2.66+2.3%$2.46$1.05▼$12.50$92.89M-0.97182,660 shs113,081 shsGTHPGuided Therapeutics$0.26-6.0%$0.25$0.06▼$0.32$22.91M0.3212,844 shs13,414 shsNTRBNutriband$7.15+6.1%$7.12$3.72▼$11.78$81.11M1.1331,957 shs21,094 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical+1.43%+3.40%-1.39%+21.02%+83.62%BDMDBaird Medical Investment+6.12%+5.26%+14.04%-63.38%+259,999,900.00%GTHPGuided Therapeutics0.00%-5.52%-0.36%+19.13%+44.21%NTRBNutriband-5.73%+7.67%+2.59%-13.03%+50.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$2.13$2.09$0.76▼$2.73$80.56M1.4356,687 shs19,303 shsBDMDBaird Medical Investment$2.66+2.3%$2.46$1.05▼$12.50$92.89M-0.97182,660 shs113,081 shsGTHPGuided Therapeutics$0.26-6.0%$0.25$0.06▼$0.32$22.91M0.3212,844 shs13,414 shsNTRBNutriband$7.15+6.1%$7.12$3.72▼$11.78$81.11M1.1331,957 shs21,094 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical+1.43%+3.40%-1.39%+21.02%+83.62%BDMDBaird Medical Investment+6.12%+5.26%+14.04%-63.38%+259,999,900.00%GTHPGuided Therapeutics0.00%-5.52%-0.36%+19.13%+44.21%NTRBNutriband-5.73%+7.67%+2.59%-13.03%+50.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 3.00BuyN/AN/ABDMDBaird Medical Investment 0.00N/AN/AN/AGTHPGuided Therapeutics 0.00N/AN/AN/ANTRBNutriband 3.00Buy$13.0081.82% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$46.51M1.73N/AN/A$0.38 per share5.61BDMDBaird Medical InvestmentN/AN/AN/AN/AN/AN/AGTHPGuided Therapeutics$10K2,152.67N/AN/A($0.12) per share-2.15NTRBNutriband$2.58M33.38N/AN/A$0.58 per share12.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$23.46M-$0.45N/AN/AN/A-37.11%-158.22%-28.30%11/7/2025 (Estimated)BDMDBaird Medical InvestmentN/AN/A0.00∞N/AN/AN/AN/AN/AGTHPGuided Therapeutics-$2.42M-$0.05N/A∞N/AN/AN/A-219.85%11/12/2025 (Estimated)NTRBNutriband-$10.48M-$2.87N/AN/AN/A-398.29%-85.40%-73.45%12/2/2025 (Estimated)Latest GTHP, BDMD, NTRB, and APYX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/9/2025Q2 2026NTRBNutriband-$0.17-$2.12-$1.95-$2.12$0.71 million$0.62 million8/14/2025Q2 2025GTHPGuided TherapeuticsN/A-$0.01N/A-$0.01N/A$0.12 million8/7/2025Q2 2025APYXApyx Medical-$0.0933-$0.09+$0.0033-$0.09$11.69 million$11.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/ABDMDBaird Medical InvestmentN/AN/AN/AN/AN/AGTHPGuided TherapeuticsN/AN/AN/AN/AN/ANTRBNutribandN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical4.614.723.95BDMDBaird Medical InvestmentN/AN/AN/AGTHPGuided TherapeuticsN/A0.130.03NTRBNutriband0.014.784.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%BDMDBaird Medical Investment19.78%GTHPGuided Therapeutics9.69%NTRBNutriband19.70%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical15.20%BDMDBaird Medical Investment78.90%GTHPGuided Therapeutics66.83%NTRBNutriband54.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27037.82 million32.07 millionOptionableBDMDBaird Medical InvestmentN/A35.73 million7.54 millionN/AGTHPGuided Therapeutics583.60 million27.73 millionNot OptionableNTRBNutriband1012.04 million5.53 millionNot OptionableGTHP, BDMD, NTRB, and APYX HeadlinesRecent News About These CompaniesNutriband (NASDAQ:NTRB) Issues Quarterly Earnings Results, Misses Expectations By $1.95 EPSSeptember 11, 2025 | marketbeat.comNutriband reports Q2 EPS ($2.12) vs. (15c) last yearSeptember 10, 2025 | msn.comNutriband Inc. Reports Strong Financial Results and Progress on AVERSA™ Fentanyl DevelopmentSeptember 10, 2025 | quiverquant.comQNutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA FentanylSeptember 10, 2025 | globenewswire.comNutriband (NASDAQ: NTRB) CEO Showcases AVERSA(TM) Abuse Deterrent Transdermal Technology at Emerging Growth ConferenceSeptember 9, 2025 | theglobeandmail.comNutriband Inc. (NTRB) Reports Q2 Loss, Lags Revenue EstimatesSeptember 9, 2025 | zacks.comNutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000September 3, 2025 | globenewswire.comNutriband (NTRB) to Release Quarterly Earnings on TuesdayAugust 27, 2025 | marketbeat.comNutriband's (NASDAQ:NTRB) investors will be pleased with their favorable 37% return over the last three yearsAugust 22, 2025 | finance.yahoo.comShort Interest in Nutriband Inc. (NASDAQ:NTRB) Drops By 39.5%August 21, 2025 | marketbeat.comNutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025August 18, 2025 | globenewswire.comNoble Financial Sticks to Their Buy Rating for Nutriband (NTRB)August 13, 2025 | theglobeandmail.comNutriband Inc.: Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential ElectionAugust 12, 2025 | finanznachrichten.deNutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential ElectionAugust 11, 2025 | globenewswire.comNutriband Inc.: FDA Grants Nutriband Meeting Request for Aversa Fentanyl Abuse Deterrent Fentanyl PatchAugust 8, 2025 | finanznachrichten.deNutriband stock rises after FDA grants meeting for fentanyl patchAugust 8, 2025 | au.investing.comFDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl PatchAugust 8, 2025 | finance.yahoo.comNutriband Shares Climb After FDA Grants Meeting for Fentanyl PatchAugust 8, 2025 | msn.comFDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl PatchAugust 8, 2025 | globenewswire.comNutriband (NASDAQ: NTRB): Innovation Meets Science Through Scalable PlatformJuly 29, 2025 | theglobeandmail.comNutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA ApprovalJuly 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGTHP, BDMD, NTRB, and APYX Company DescriptionsApyx Medical NASDAQ:APYX$2.13 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.16 +0.03 (+1.60%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Baird Medical Investment NASDAQ:BDMD$2.66 +0.06 (+2.31%) As of 04:00 PM EasternBaird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.Guided Therapeutics OTCMKTS:GTHP$0.26 -0.02 (-6.02%) As of 03:31 PM EasternGuided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.Nutriband NASDAQ:NTRB$7.15 +0.41 (+6.08%) Closing price 04:00 PM EasternExtended Trading$6.98 -0.18 (-2.45%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
